Brief: Y-mAbs Appoints Norman LaFrance As Chief Development Officer
05/06/2024 13:22
June 5 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O :
* Y-MABS DEEPENS RADIOPHARMACEUTICAL LEADERSHIP WITH
APPOINTMENT
OF NORMAN LAFRANCE, M.D. AS CHIEF DEVELOPMENT OFFICER
Source text for Eikon: ID:nGNXc5W1kx
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Y-mAbs Therapeutics
See all newsY-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary